Skip to main content
. 2023 Feb 13;78(4):991–999. doi: 10.1093/jac/dkad033

Figure 4.

Figure 4.

In vivo dose-fractionation study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with NDM-1-positive K. pneumoniae ATCC BAA-2473 (mean ± SD, n = 3). Aztreonam was administered every 2 h, and nacubactam was administered with variable frequency: every 2 h, every 4 h and every 8 h.